Reauthorization of PDUFA: What It Means for Jobs, Innovation, and Patients
Wednesday, February 1, 2012 - 10:00am
Location:
2123 Rayburn
Reauthorization of PDUFA: What It Means for Jobs, Innovation, and Patients
Background Documents and Information:
Opening Statements:
Panel I
The Honorable Margaret A. Hamburg, M.D.
- Commissioner
- U.S. Food and Drug Administration
- Witness Testimony (Truth in Testimony)
Panel II
Mr. Geno Germano
- President and General Manager
- Specialty Care and Oncology
- Pfizer, Inc.
- Witness Testimony (Truth in Testimony)
Dr. David L. Gollaher
- President and CEO
- CHI-California Healthcare Institute
- Witness Testimony (Truth in Testimony)
Mr. Richard F. Pops
- Chairman and CEO
- Alkermes
- On behalf of
- Biotechnology Industry Organization
- Witness Testimony (Truth in Testimony)
Mr. Allan Coukell
- Director, Medical Programs
- Pew Health Group
- The Pew Charitable Trusts
- Witness Testimony (Truth in Testimony)
Ms. Diane Edquist Dorman
- Vice President
- Public Policy
- National Organization of Rare Disorders
- Witness Testimony (Truth in Testimony)
Dr. David E. Wheadon
- Senior Vice President
- Scientific and Regulatory Affairs
- Pharmaceutical Research and Manufacturers of America
- Witness Testimony (Truth in Testimony)
Dr. Daniel A.C. Frattarelli
- Chair, American Academy of Pediatrics’ Committee on Drugs
- Oakwood Hospital and Medical Center and Medical Center
- On behalf of
- American Academy of Pediatrics' Committee on Drugs
- Witness Testimony (Truth in Testimony)